OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun
Maristella Bungaro, Silvia Novello, Francesco Passiglia
Current Treatment Options in Oncology (2022) Vol. 23, Iss. 12, pp. 1699-1720
Closed Access | Times Cited: 11
Maristella Bungaro, Silvia Novello, Francesco Passiglia
Current Treatment Options in Oncology (2022) Vol. 23, Iss. 12, pp. 1699-1720
Closed Access | Times Cited: 11
Showing 11 citing articles:
Advances in the Molecular Landscape of Lung Cancer Brain Metastasis
Vanessa G. P. Souza, Rachel Paes de Araújo, Mariana R. Santesso, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 722-722
Open Access | Times Cited: 18
Vanessa G. P. Souza, Rachel Paes de Araújo, Mariana R. Santesso, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 722-722
Open Access | Times Cited: 18
Discovery of Potent SOS1 PROTACs with Effective Antitumor Activities against NCI-H358 Tumor Cells In Vitro/In Vivo
Xudong Pang, Dawei Cui, Binhua Lv, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 2, pp. 1563-1579
Closed Access | Times Cited: 5
Xudong Pang, Dawei Cui, Binhua Lv, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 2, pp. 1563-1579
Closed Access | Times Cited: 5
Exploring Cellular Plasticity and Resistance Mechanisms in Lung Cancer: Innovations and Emerging Therapies
Caiyu Jiang, Shenglong Xie, Kegang Jia, et al.
Journal of Pharmaceutical Analysis (2025), pp. 101179-101179
Open Access
Caiyu Jiang, Shenglong Xie, Kegang Jia, et al.
Journal of Pharmaceutical Analysis (2025), pp. 101179-101179
Open Access
Chaperone Directed Heterobifunctional Molecules Circumvent Krasg12c Inhibitor Resistance
Takeshi Shimamura, Inés Pulido, Qiyue Luan, et al.
(2025)
Closed Access
Takeshi Shimamura, Inés Pulido, Qiyue Luan, et al.
(2025)
Closed Access
Chaperone directed heterobifunctional molecules circumvent KRASG12C inhibitor resistance.
Inés Pulido, Qiyue Luan, Sara Pastor-Puente, et al.
Cancer Letters (2025), pp. 217691-217691
Open Access
Inés Pulido, Qiyue Luan, Sara Pastor-Puente, et al.
Cancer Letters (2025), pp. 217691-217691
Open Access
The importance of protein domain mutations in cancer therapy
Kiran Kumar Chitluri, Isaac Arnold Emerson
Heliyon (2024) Vol. 10, Iss. 6, pp. e27655-e27655
Open Access | Times Cited: 3
Kiran Kumar Chitluri, Isaac Arnold Emerson
Heliyon (2024) Vol. 10, Iss. 6, pp. e27655-e27655
Open Access | Times Cited: 3
Targeting of SOS1: from SOS1 Activators to Proteolysis Targeting Chimeras
Gerhard Hamilton, Sandra Stickler, Barbara H. Rath
Current Pharmaceutical Design (2023) Vol. 29, Iss. 22, pp. 1741-1746
Closed Access | Times Cited: 5
Gerhard Hamilton, Sandra Stickler, Barbara H. Rath
Current Pharmaceutical Design (2023) Vol. 29, Iss. 22, pp. 1741-1746
Closed Access | Times Cited: 5
Response to First-Line Pembrolizumab in Metastatic KRAS -Mutated Non-Small-Cell Lung Cancer
Sabrina Rossi, Arianna Pagliaro, Giovanna Finocchiaro, et al.
Future Oncology (2024) Vol. 20, Iss. 7, pp. 373-380
Closed Access | Times Cited: 1
Sabrina Rossi, Arianna Pagliaro, Giovanna Finocchiaro, et al.
Future Oncology (2024) Vol. 20, Iss. 7, pp. 373-380
Closed Access | Times Cited: 1
How to Keep Up With Molecular Testing and Targeted Therapies in Lung Cancer
Jyoti Malhotra, Edward S. Kim
JCO Oncology Practice (2024) Vol. 20, Iss. 11, pp. 1471-1480
Closed Access | Times Cited: 1
Jyoti Malhotra, Edward S. Kim
JCO Oncology Practice (2024) Vol. 20, Iss. 11, pp. 1471-1480
Closed Access | Times Cited: 1
Construction and analysis of the CDKN2B-AS1 ceRNA network associated with KRAS-dependent tumorigenesis in colorectal and pancreatic cancer
Mahsa Saliani, Ali Javadmanesh, Parisa Gonbadi, et al.
Research Square (Research Square) (2024)
Open Access
Mahsa Saliani, Ali Javadmanesh, Parisa Gonbadi, et al.
Research Square (Research Square) (2024)
Open Access
KRAS combination strategies: How well aligned is clinical and preclinical research?
Ernest Nadal, Chiara Ambrogio, David Santamarı́a, et al.
Elsevier eBooks (2024), pp. 417-441
Closed Access
Ernest Nadal, Chiara Ambrogio, David Santamarı́a, et al.
Elsevier eBooks (2024), pp. 417-441
Closed Access
Expanding the KRASG12C Inhibitor Class: What Do We Need Next?
Aurora Norman, Alex A. Adjei
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 7, pp. 844-846
Open Access | Times Cited: 1
Aurora Norman, Alex A. Adjei
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 7, pp. 844-846
Open Access | Times Cited: 1
